How many times have you started to have a conversation with someone about Hepatitis C only to have it blow up in your face? Have you ever heard someone say something about Hep C that didn't seem quite right to you? You were probably right something was amiss. A discussion about Hepatitis C can...
As per Wikipedia, the definition of a stigma is as follows: "Stigma is a word that originally means a "sign", "point", or "branding mark"." Wikipedia goes on to call stigma "A badge of shame, a physical mark of infamy or disgrace." Damn that w...
Recently, the CDC (Center for Disease Control) issued a statement that all Baby Boomers should be tested for Hepatitis C. The question often comes up as to why this particular segment of people is so vulnerable. What does being born between 1945 and 1965 have to do with Hepatitis C? What was di...
Buyer Beware! There are several snake oil salesmen out there who are claiming to have cured their own Hepatitis C with herbs, supplements and parking lot gravel. Okay, maybe not the parking lot gravel but it might as well be. What you need to remember is that there are two different types of...
Most every adult woman (and an occasional man) has enjoyed a manicure and a pedicure at a nail salon or spa. That 30 minute pedicure can be so relaxing but are you aware of the danger lurking in that nail salon? Although few individuals recognize the medical risks associated with this common pr...
AIDSTAR-One is funded by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Agency for International Development (USAID), and provides rapid technical assistance to USAID and U.S. Government country teams to build effective, well-managed, and sustainable HIV and AIDS programs, and promotes new leadership in the global campaign against HIV.
During the recent International AIDS Society Conference in Washington, DC, exciting breakthroughs in HIV prevention, treatment, and care—even a possible cure—took center stage. But despite recent advances, many men and women remain at risk of HIV as a result of structural issues that fuel and have an impact on the epidemic.
Structural Interventions reduce individual HIV-related vulnerability by creating conditions that enable people to adopt safer behaviors. Addressing gender inequality, poverty, stigma, and other social, economic, cultural, and legal factors is necessary to create an “enabling environment” for these promising biomedical and behavioral interventions.
There is increasing agreement worldwide that structural issues are too often overlooked where HIV prevalence remains high. Women who are not empowered to take charge of their sexual lives cannot practice HIV prevention, be it in the form of condoms or pre-exposure prophylaxis. Most-at-risk populations, such as men who have sex with men, will not seek out prevention and care services if they fear stigma or prosecution. Countries that cannot afford an extensive public health network cannot offer voluntary medical male circumcision or antiretroviral therapy to its rural citizens.
Unfortunately, specific operational guidelines, definitions, and evidence to clearly guide implementation of scalable structural approaches remain inadequate. To fill this gap, the U.S. Government and the global HIV community are working toward achieving consensus on how to prioritize which structural interventions. Addressing structural drivers can have a tremendous impact on the epidemic, but bringing promising approaches to scale requires sustained investment, a significant challenge in the face of competing priorities and tightening budgets.
Recent PEPFAR guidance recognizes the importance of addressing structural drivers as part of a comprehensive combination prevention package of services. At the International AIDS Conference, USAID – along with other U.S. Government agency staff, implementers, researchers, and policymakers – discussed the structural issues that impede progress, with the goal of building consensus to move forward.
The challenge is figuring out which structural approaches will achieve the maximum impact within different contexts. Implementers at the community level know that addressing structural drivers—which are deeply entrenched in social, economic, and political systems—requires sustained investments with strategies tailored to local contexts. Identifying what works is also difficult. Although there is increasing evidence that supports the links between these factors and HIV, measuring change can often be hard in relatively short-term project lifecycles. Experts also disagree on which types of evaluation methods are adequate to demonstrate change, and balancing the need to address these factors while also scaling up other proven interventions continues to be a challenge. Because structural drivers are linked to the very fabric of social, economic, and political systems, they often require a broader sector response, unlike more narrow biomedical and behavioral approaches.
Nonetheless, and despite the existence of clear guidance, some countries are making great progress in this area. For example, Zambia is integrating structural approaches into its national HIV framework through a multisectoral response. Key successes in Zambia’s national strategy have been strengthening collaboration and coordination across sectors and investing in a community-driven process. Panelists at a satellite session on the topic at the International AIDS Conference discussed some of these initiatives. For example, the Zambia Land Alliance is working with local authorities to ensure the availability of land for vulnerable populations, which helps address the lack of access to property that increases women’s vulnerability.
The best strategies for lifting structural barriers will be context specific, and will ultimately come from local communities. But to achieve widespread success, the response will also have to be coordinated with and supported by national and international strategies and—given limited resources—strategically integrated into other combination prevention program areas. Easier said than done, but acknowledging the challenges and building consensus are two positive steps in moving one stubborn gorilla.
Please sign the ATC Salvage Therapy Petition Join us in asking Congressman Alcee Hastings and Congresswomen Maxine Waters to send a ‘Dear Colleague’ letter to Anthony Fauci, Director of NIAID, asking for the federal facilitation of apricitabine (ATC). ATC is a phase III nucleoside reverse transcriptase inhibitor (NRTI) that has been shown to be safe and effective in treating people with HIV. It works against viruses that are resistant to several other nukes and could ...
Researchers from Johns Hopkins Children’s Center, the University of Mississippi Medical Center and the University of Massachusetts Medical School announced today at CROI2013 the discovery of the first infant functionally cured of HIV. The baby, a female now two and a half years old, received 3 HIV medications when brought to the hospital at 30 hours old. Viral load tests were performed during the first few weeks that showed a rapidly decreasing viral load which reached ...
At the 19th International AIDS Conference (AIDS 2012) in Washington D.C., the CDC reported that only 1 out of 4 HIV patients in the U.S. have HIV under control, which is defined as complete viral suppression. Warning bells should be ringing in the scientific and HIV advocacy communities. While much progress has been made in the last three decades in the treatment of HIV, tens of thousands of people living with HIV (PLWH) are currently struggling to construct viable treat...
Paige Rawl is 17 and HIV positive, but while her life has been shaped by HIV it isn't ruled by it. When Paige Rawl starts her senior year at Indianapolis’s Herron High School next month, she'll be cheer captain and a member of the student government and prom committee. This summer, the 17-year-old held down a part-time job at Hollister, hawking the popular Southern California-inspired clothing brand. The all-American girl — who happens to be HIV positive. Paige was in...
The HIV community has been abuzz with the August FDA approval of what had been termed “the Quad”, the second one-pill-once-a-day combination antiretroviral drug. Marketed by Gilead under the name Stribild, the drug contains two NRTIs (tenofovir and emtricitabine), an integrase inhibitor (elvitegravir) and an integrase booster (cobicistat) and is approved for use in treatment naïve patients with either drug resistant or wild type virus. In comparison to Atripla, the first...

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for SUSTIVA® (efavirenz), including dosing recommendations for...

California and other states would be pressured to amend or repeal criminal laws that single out HIV-positive people under a bipartisan bill co-authored and introduced this week by Rep. Barbara...
Mission Statement
At HIV Haven we wish to provide our readers with vital cutting edge information to help expand HIV knowledge and promote activism, particularly that which works towards an end to the HIV pandemic. It is our desire to bring to you the scientific, medical and social advances that given the appropriate attention and support, could change the course of the HIV pandemic, lessen the devastating effects of HIV and AIDS, better the quality and quantity of life for people living with HIV and even yield an eventual end to the HIV pandemic. We also provide the basics of HIV transmission and treatment.
We will focus on issues such as innovative drug development, strategic activist campaigns, HIV relationships and novel HIV and HIV cure research. We also will bring you advances in Hepatitis C (HCV), a common HIV co-infection. Whether you are living with HIV/AIDS, HIV and HCV, love someone who is, are an activist, advocate, researcher, physician or just an interested party, we hope here at HIV Haven we can help you find what you are looking for.